Medicare AdvantageCoverageMedium impact
MA08.152d, Nivolumab and relatlimab-rmbw (Opdualag™) for intravenous use
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.152d for Nivolumab and relatlimab-rmbw (Opdualag™) intravenous therapy has been reissued with an effective date of March 4, 2026. This is a fresh policy update that may contain new coverage criteria, prior authorization requirements, or billing guidelines for this combination immunotherapy drug.
Action Required
By March 4, 2026: Billing and clinical teams should review the updated MA08.152d policy for Nivolumab and relatlimab-rmbw (Opdualag™) at the provided URL to identify any changes in coverage criteria, prior authorization requirements, or billing procedures. Update internal protocols and staff training accordingly to ensure compliance with the new policy requirements.